BioNTech shares are crashing as the company posted a disappointing Q4 release and announced cofounders departure by the end of 2026. Here’s why BNTX stock is still worth buying today.
Pfizer is looking to sell its remaining stake in Covid-19 vaccine partner BioNTech. Have the good days finally come to an end?
In a report released today, Geoff Meacham from Citi maintained a Buy rating on BioNTech SE. The company’s shares opened today at $101.91.Elevate Your Investing Strategy: Take advantage of TipRanks Premium...
TD Cowen analyst Yaron Werber maintained a Hold rating on BioNTech SE today and set a price target of $120.00. The company’s shares closed yesterday at $102.21.Elevate Your Investing Strategy: Take advantage...
In a report released on September 30, Evan Seigerman from BMO Capital assigned a Buy rating to BioNTech SE, with a price target of $143.00. The company’s shares closed yesterday at $102.21.Elevate Your...
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NASDAQ:CRSP),(NASDAQ:BNTX),(NYSE:BMY) EQNX::TICKER_END
/CNW/ -- Cell therapy refers to a treatment that involves the use of living cells to treat diseases. The cell therapy market has been experiencing significant...
MarketNewsUpdates News Commentary
September S&P 500 E-Mini futures (ESU25) are up +0.19%, and September Nasdaq 100 E-Mini futures (NQU25) are up +0.08% this morning, pointing to a slightly higher open on Wall Street amid optimism ahead...
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The FDA's unprecedented accelerated approval pace through August 2025 has delivered breakthrough treatments...